BOSTON, MA — November 17, 2021 — Emulate, Inc., a leading provider of next-generation in vitro models, announced today that it ranked No. 208 on the Deloitte Technology Fast 500™, an annual list of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 27th year.
Emulate’s Chief Executive Officer, Jim Corbett, attributes the company’s revenue growth to the strength of talent throughout the Emulate team, the expansion of Emulate’s Organ-on-a-Chip application offerings, and simultaneous policy commitments that advocate for the use of animal model alternatives in drug development. “Despite the challenges of an unprecedented year, Emulate’s success can be attributed to a variety of factors that will continue to drive momentum through 2022 and beyond,” he said. “We have scaled our team to include scientific expertise that aligns with our application roadmap and commercial leaders from across the life sciences industry. We have also deepened our portfolio of human-relevant Organ-on-a-Chip models with the introduction of the Brain-Chip and the Colon Intestine-Chip, and we have reinforced our commitment to reduce animal testing by joining the North American 3Rs collaborative as well as supporting the FDA Modernization Act and the Humane Research Act.”
“Each year the Technology Fast 500 shines a light on leading innovators in technology, and this year is no exception,” said Paul Silverglate, vice chair, Deloitte LLP and U.S. technology sector leader. “In the face of innumerable challenges resulting from the pandemic, the best and brightest were able to pivot, reinvent, transform and grow. We celebrate the winning organizations and especially the talented employees driving their success.”
“The pandemic has underscored the urgent need for tech solutions in a variety of areas across health care, fintech, energy tech, and entertainment, to name a few, so reliance on innovators like the winners of the Technology Fast 500 is more important than ever,” said Christie Simons, partner, Deloitte & Touche LLP and industry leader for technology, media, and telecommunications within Deloitte’s audit & assurance practice. “These companies are at the cutting edge, transforming the way we do business, but—most importantly—they also recognize the strategic importance of ongoing innovation, especially in the ever-changing world of technology.”
About the 2021 Deloitte Technology Fast 500™
Now in its 27th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies—both public and private—in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2017 to 2020.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000 and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.
About Emulate, Inc.
Emulate is igniting a new era in human health with industry-leading Organ-on-a-Chip technology. The Human Emulation System provides a window into the inner workings of human biology and disease, offering researchers an innovative technology designed to predict human response with greater precision and detail than conventional cell culture or animal-based experimental testing. Pioneered at the Wyss Institute for Biologically Inspired Engineering at Harvard University and backed by Northpond Ventures, Founders Fund, and Perceptive Advisors, Organ-on-a-Chip technology is assisting researchers across academia, pharma, and government industries through its predictive power and ability to recreate true-to-life human biology. To learn more, visit emulatebio.com or follow us on LinkedIn and Twitter.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.
Michael Sullivan for Emulate